The global anti-obesity drugs market is estimated to have reached $1.9bn in 2019 and is expected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the innovator drugs submarket held 75% of the global anti-obesity drugs market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 285-page report you will receive 146 tables and 137 figures– all unavailable elsewhere.
The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Anti-obesity Drugs Market forecast from 2020-2030
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action: • Incretion mimetics/GLP-1 agonists • SNDRIs • Lipase Inhibitors • Serotonin receptor agonists • Sympathomimetic-GABA receptor agonists • Sympathomimetics
• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy: • Long-term Drugs • Short-term Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs: • Innovator • Generic Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC: • Prescription Drugs • OTC
• This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs: • Saxenda • Contrave/Mysimba • Belviq • Qysmia • Xenical • Alli
• This report provides individual revenue forecasts from 2020-2030 for these regional and national markets: • US • Japan • EU5: Germany, France, Spain, Italy, UK • BRIC: Brazil, Russia, China, India • RoW
Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs.
• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market: • Arena Pharmaceuticals • AstraZeneca • Carmot Therapeutics • CohBar • Currax Pharmaceuticals LLC • Eisai • ERX Pharmaceuticals • Gelesis • GlaxoSmithKline (GSK) • Hanmi Pharmaceutical • LNC Therapeutics • Novartis • Novo Nordisk • Pfizer • Rhythm Pharmaceuticals, Inc. • Roche • Saniona • Scohia Pharma, Inc. • Sinil Pharmaceutical Co., Ltd • Takeda • Teva • Vivus
• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
• This report gives an overview of pricing and reimbursement in the US and EU.
• This report provides a SWOT Analysis of the global anti-obesity drugs market.
• Key questions answered by this report: • How is the anti-obesity drugs market evolving? • What is driving and restraining anti-obesity drugs dynamics? • How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030? • How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to? • Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030? • How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets? • Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy? • How will market shares of the national markets change by 2030 and which nation will lead the market in 2030? • Who are the leading players and what are their prospects over the forecast period? • How will the sector evolve as alliances form during the period between 2020 and 2030?
Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report:
1.4 Who is This Report for?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions
1.7 Associated Reports
1.8 About Visiongain
2. Introduction to Obesity
2.1 What is Obesity?
2.1.1 Types of obesity
2.1.1.1 Central Obesity / Android Type
2.1.1.2 Peripheral Obesity/ Gynoid Type
2.2 What are the causes and risk factors of obesity?
2.2.1 Energy Imbalance
2.2.2 Genetic Predisposition
2.2.3 Unhealthy Diet
2.2.4 Health Conditions and Medicines
2.2.5 Emotional Factors
2.2.6 Age
2.2.7 Pregnancy
2.2.8 Lack of Sleep
2.2.9 Smoking
2.3 Obesity Measurement
2.3.1 BMI
2.3.2 Waist circumference
2.3.3 Index of Central Obesity
2.3.4 Bioelectrical Impedance Analysis
2.3.5 New Approaches/Techniques
2.4 Epidemiology of Obesity
2.4.1 Epidemiology by Geography
2.4.2 Epidemiology by Country
2.4.3 Historical Prevalence in Major Markets
2.4.4 Forecast of Obesity Prevalence in Major Markets
2.5 Humanistic and Economic Burden
2.5.1 Mortality
2.5.2 Morbidity
2.5.2.1 Disability-adjusted life year (DALY)
2.5.2.2 Years Lost due to Disability (YLD)
2.5.2.3 Years of Life Lost (YLL)
2.5.3 Economic Impact
2.6 Obesity: Prevention and Treatment
2.6.1 Lifestyle changes
2.6.2 Pharmacotherapy
2.6.3 Other treatments
3. Introduction to the Global Anti-obesity Drugs Market
6.6.1.1 China Anti-obesity Drugs: Market Forecasts 2020-2030
6.6.1.2 India Anti-obesity Drugs: Market Forecasts 2020-2030
6.6.1.3 Brazil Anti-obesity Drugs: Market Forecasts 2020-2030
6.6.1.4 Russia Anti-obesity Drugs: Market Forecasts 2020-2030
7. Research and Development for Treating Obesity
7.1 Novel Mechanism of Action of Pipeline Drugs
7.2 Active Pipeline Molecules
7.3 Promising Potential Pipeline Molecules
7.3.1 Phase III Molecules
7.3.1.1 BTI-320
7.3.2 Phase II Molecules
7.3.2.1 Oxyntolong
7.3.2.2 Antisense FGFR4 oligo, Verva
7.3.2.3 S-237648
7.3.2.4 Setmelanotide
7.3.2.5 Bupropion + zonisamide SR
7.3.2.6 Semaglutide
7.3.2.7 LIK066
7.3.2.8 Tesofensine
7.3.2.9 LIPO-202
7.3.2.10 Canagliflozin and Phentermine
7.3.2.11 OBEP-100
7.3.2.12 Efpeglenatide
7.3.2.13 EMP16
7.3.2.14 MEDI-0382
8. Pricing and Reimbursement Overview
8.1 US
8.2 EU
8.3 Payers Perspective
9. Qualitative Analysis of the Global Anti-obesity Drugs Market
9.1 SWOT Analysis, 2019
9.2 Market Trends in Weight Loss & Management Market
10. Leading Companies in Global Anti-obesity Drugs Market, 2019
10.1 Novo Nordisk
10.1.1 Obesity Care – To Establish its presence
10.2 Currax Pharmaceuticals LLC
10.2.1 Currax™ Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
10.3 Eisai Co., Ltd.
10.3.1 Collaboration Agreement with EUROFARMA
10.3.2 Collaboration Agreement with CY BIOTECH
10.4 F. Hoffmann-La Roche Ltd.
10.5 Vivus
10.5.1 Collaboration Agreement with Alvogen Malta Operations (ROW) Ltd
10.5.2 Collaboration Agreement with Other Companies
10.6 Teva
10.7 GlaxoSmithKline (GSK)
10.8 Pfizer Inc.
10.9 Rhythm Pharmaceuticals, Inc.
10.10 AstraZeneca
10.11 Saniona
10.12 Hanmi Pharmaceutical
10.13 SCOHIA PHARMA, Inc.
10.14 Sinil Pharmaceutical Co., Ltd
10.15 ERX Pharmaceuticals
10.16 CohBar, Inc.
10.17 Carmot Therapeutics, Inc.
10.18 LNC Therapeutics
10.19 Gelesis
11. Conclusions
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Table
Table 2.1 WHO BMI Cut Off Points
Table 2.2 Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk
Table 2.3 Prevalence of obesity among adults (both sexes 18+), BMI ≥ 30, age-standardized Estimates by WHO region
Table 2.4 Prevalence of obesity (Male 18+), BMI ≥ 30, age-standardized Estimates by WHO region
Table 2.5 Prevalence of obesity (Female 18+), BMI ≥ 30, age-standardized Estimates by WHO region
Table 2.6 Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2019-2030, million, CAGR% (2019-2030)
Table 3.1 Mechanism of Action of Innovator Drugs for the treatment of Obesity
Table 3.2 List of Innovator Drugs for the treatment of Obesity
Table 3.2 List of Prescription Drugs for the treatment of Obesity
Table 3.3 Long-term Prescription Drugs for the treatment of Obesity
Table 4.1 Global Anti-obesity Drugs Market by Markets: Revenue ($m), and Market Share (%), 2019
Myeloproliferative Disorders Drugs– our new study reveals trends, R&D progress, and predicted revenues Where is the Myeloproliferative Disorders Drugs market...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
